Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
DURHAM, N.C., April 26, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced today that Jeff Wolf, Heat’s Founder and CEO, will present at PIONEERS 2017, presented by Joseph Gunnar & Co., on Tuesday, May 2, 2017, at 11:30 a.m. ET. The event will be held at the Mandarin Oriental Hotel in New York City.
Management will be available to meet with investors during the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Joseph Gunnar & Co. representative, email [email protected] or email [email protected].
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that robustly activates the immune system. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
For Investor Inquiries: David Waldman 919-240-7133 [email protected] For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 [email protected]
